scholarly journals A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

Diabetes Care ◽  
2009 ◽  
Vol 32 (9) ◽  
pp. 1656-1662 ◽  
Author(s):  
J. P.H. Wilding ◽  
P. Norwood ◽  
C. T'joen ◽  
A. Bastien ◽  
J. F. List ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Sensitizers ◽  
High Doses

Efficacy and cardiovascular safety of Thiazolidinediones

2020 ◽  
Vol 15 ◽  
Author(s):  
Raveendran Arkiath Veettil ◽  
Cornelius James Fernandez ◽  
Koshy Jacob
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Glucose Transporter ◽  
Cell Function ◽  
Cardiovascular Safety ◽  
Cardiovascular Outcome Trials ◽  
Glucose Transporter 2 ◽  
Insulin Sensitizers

: Type 2 diabetes mellitus (T2DM) is characterized by a progressive beta cell dysfunction in the setting of peripheral insulin resistance. Insulin resistance in subjects with type 2 diabetes and metabolic syndrome is primarily caused by an ectopic fat accumulation in liver and skeletal muscle. Insulin sensitizers are particularly important in the management of T2DM. Though, thiazolidinediones (TZDs) are principally insulin sensitizers, they possess an ability to preserve pancreatic β-cell function and thereby exhibit durable glycemic control. Cardiovascular outcome trials (CVOTs) have shown that Glucagon-like-peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose transporter-2 inhibitors (SGLT2i) have proven cardiovascular safety. In this era of CVOTs, drugs with proven cardiovascular (CV) safety are often preferred in patients with preexisting cardiovascular disease or at risk of cardiovascular disease. In this review, we will describe the three available drugs belonging to the TZD family, with special emphasis on their efficacy and CV safety.

Clinico-metabolic profile of a group of women with type 2 diabetes with high doses of insulin

2018 ◽  
Vol 275 ◽  
pp. e199-e200
Author(s):  
C. Jemai ◽  
N. Ben Amor ◽  
M. Zarrouk ◽  
H. Tertek ◽  
A. Temessek ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Profile ◽  
High Doses

Molecular Electrostatic Potentials in the Design of Dendrimers for the Delivery of Glitazones

2006 ◽  
Vol 6 (9) ◽  
pp. 3277-3282 ◽  
Author(s):  
Prasad V. Bharatam ◽  
Sandeep Sundriyal
Keyword(s):  
Type 2 Diabetes ◽  
Drug Delivery ◽  
Hydrogen Bonds ◽  
Ab Initio ◽  
Electrostatic Potential ◽  
Molecular Electrostatic Potentials ◽  
Mo Calculations ◽  
Binding Strength ◽  
Insulin Sensitizers

Glitazones are PPARγ agonistic insulin sensitizers used clinically for the treatment of type-2 diabetes. The delivery of these compounds with the help of dendrimers is possible. Ab initio MO calculations and MESP analysis indicate that the dendrimers with complementary electrostatic potential to glitazones can be designed. The estimated binding strength between one arm of dendrimer and thiazolidinedione is about 15–20 kcal/mol. This binding strength originates from three hydrogen bonds between the dendrimer and each molecule of glitazone. This binding strength is quite suitable for drug encapsulation on the dendrimer based nanoparticles and can be employed for drug delivery.

scholarly journals Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

2013 ◽  
Vol 16 (2) ◽  
pp. 124-136 ◽  
Author(s):  
J. P. H. Wilding ◽  
V. Woo ◽  
K. Rohwedder ◽  
J. Sugg ◽  
S. Parikh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Efficacy And Safety ◽  
High Doses

Use of Continuous Subcutaneous Insulin Infusion Pump in Patients With Type 2 Diabetes Mellitus

2005 ◽  
Vol 31 (6) ◽  
pp. 843-848 ◽  
Author(s):  
Susan Nielsen ◽  
Donna Kain ◽  
Elizabeth Szudzik ◽  
Sandeep Dhindsa ◽  
Rajesh Garg ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Homeostasis ◽  
Insulin Infusion ◽  
Infusion Pump ◽  
Hypoglycemic Agents ◽  
Management Problem ◽  
Oral Hypoglycemic Agents ◽  
High Doses ◽  
Hba1c Levels

Purpose In patients with type 2 diabetes, the control of hyperglycemia is often difficult despite full doses of oral hypoglycemic agents and extremely large doses of insulin. These patients pose a major management problem. The authors therefore investigated whether insulin given as a subcutaneous continuous infusion of insulin (CSII) would result in an improvement in glucose homeostasis. Methods Four patients with badly controlled type 2 diabetes, on treatment with extremely high doses of insulin and oral hypoglycemic agents, were started on CSII. Results All four patients had a marked improvement in plasma glucose concentrations with a corresponding fall in HbA1c levels. This improvement was associated with a marked fall in the insulin doses necessary to maintain adequate glucose homeostasis. Conclusions Since HbA1c levels fell from levels that would be associated with diabetic complications to those at which complications are markedly reduced, we recommend that patients with type 2 diabetes uncontrolled on extremely high doses of insulin be given a trial of treatment with CSII.

Sign in / Sign up

Export Citation Format

Share Document